Azithromycin for prevention of exacerbations in severe asthma (AZISAST): A multicentre randomised double-blind placebo-controlled trial

Thorax

Volumn 68, Issue 4, 2013, Pages 322-329

  Brusselle, Guy G ^a   VanderStichele, Christine ^a   Jordens, Paul ^b   Deman, René ^c   Slabbynck, Hans ^d   Ringoet, Veerle ^d   Verleden, Geert ^e   Demedts, Ingel K ^f   Verhamme, Katia ^g   Delporte, Anja ^a   Demeyere, Bénédicte ^a   Claeys, Geert ^a   Boelens, Jerina ^a   Padalko, Elizaveta ^a   Verschakelen, Johny ^e   Van Maele, Georges ^a   Deschepper, Ellen ^a   Joos, Guy F P ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b OLV HOSPITAL   (Belgium)

^c AZ GROENINGE   (Belgium)

^d ZNA Middelheim ^*  (Belgium)

^e UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^f Heilig Hart Ziekenhuis   (Belgium)

^g ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; LONG ACTING DRUG; PLACEBO;

ADD ON THERAPY; ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; ASTHMA; ASTHMA CONTROL QUESTIONNAIRE; ASTHMA QUALITY OF LIFE QUESTIONNAIRE; CONTROLLED STUDY; DISEASE EXACERBATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; EOSINOPHILIA; FEMALE; HEARING IMPAIRMENT; HUMAN; LOW DRUG DOSE; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OROPHARYNX; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; STREPTOCOCCUS; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

EID: 84875219719     PISSN: 00406376     EISSN: 14683296     Source Type: Journal    
DOI: 10.1136/thoraxjnl-2012-202698     Document Type: Article

References (33)

1. Wenzel SE. Asthma: defining of the persistent adult phenotypes. Lancet 2006;368:804-13. (Pubitemid 44279058)
2. The ENFUMOSA cross-sectional European multicentre study of the clinical phenotype of chronic severe asthma. European Network for Understanding Mechanisms of Severe Asthma. Eur Respir J 2003;22:470-7.
3. Haselkorn T, Fish JE, Zeiger RS, et al. Consistently very poorly controlled asthma, as defined by the impairment domain of the Expert Panel Report 3 guidelines, increases risk for future severe asthma exacerbations in The Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens (TENOR) study. J Allergy Clin Immunol 2009;124:895-902 e1-4.
4. Moore WC, Meyers DA, Wenzel SE, et al. Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program. Am J Respir Crit Care Med 2010;181:315-23.
5. McGrath KW, Icitovic N, Boushey HA, et al. A large subgroup of mild-to-moderate asthma is persistently noneosinophilic. Am J Respir Crit Care Med 2012;185:612-19.
6. Green RH, Brightling CE, Woltmann G, et al. Analysis of induced sputum in adults with asthma: identification of subgroup with isolated sputum neutrophilia and poor response to inhaled corticosteroids. Thorax 2002;57:875-9. (Pubitemid 35178612)
7. Thomson NC, Chaudhuri R, Livingston E. Asthma and cigarette smoking. Eur Respir J 2004;24:822-33. (Pubitemid 39504438)
8. Crosbie PAJ, Woodhead MA. Long-term macrolide therapy in chronic inflammatory airway diseases. Eur Respir J 2009;33:171-81.
9. Equi A, Balfour-Lynn IM, Bush A, et al. Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial. Lancet 2002;360:978-84. (Pubitemid 35284109)
10. Davies G, Wilson R. Prophylactic antibiotic treatment of bronchiectasis with azithromycin. Thorax 2004;59:540-1. (Pubitemid 38797534)
11. Wong C, Jayaram L, Karalus N, et al. Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial. Lancet 2012;380:660-7.
12. Koyama H, Geddes DM. Erythromycin and diffuse panbronchiolitis. Thorax 1997;52:915-18. (Pubitemid 27473937)
13. Coeman M, Van Durme Y, Bauters F, et al. Neomacrolides in the treatment of patients with severe asthma and/or bronchiectasis: a retrospective observational study. Ther Adv Respir Dis 2011;5:377-86.
14. Seemungal TA, Wilkinson TM, Hurst JR, et al. Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations. Am J Respir Crit Care Med 2008;178:1139-47.
15. Albert RK, Connett J, Bailey WC, et al. Azithromycin for prevention of exacerbations of COPD. N Engl J Med 2011;365:689-98.
16. Brusselle GG, Joos GF, Bracke KR. New insights into the immunology of chronic obstructive pulmonary disease. Lancet 2011;378:1015-26.
17. Reddel HK, Taylor DR, Bateman ED, et al. An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. Am J Respir Crit Care Med 2009;180:59-99.
18. Keene ON, Calverley PM, Jones PW, et al. Statistical analysis of COPD exacerbations. Eur Respir J 2008;32:1421-2.
19. Kraft M, Cassell GH, Pak J, et al. Mycoplasma pneumoniae and Chlamydia pneumoniae in asthma: effect of clarithromycin. Chest 2002;121:1782-8. (Pubitemid 34634396)
20. Black PN, Blasi F, Jenkins CR, et al. Trial of roxithromycin in subjects with asthma and serological evidence of infection with Chlamydia pneumoniae. Am J Respir Crit Care Med 2001;164:536-41. (Pubitemid 32801652)
21. Shoji T, Yoshida S, Sakamoto H, et al. Anti-inflammatory effect of roxithromycin in patients with aspirin-intolerant asthma. Clin Exp Allergy 1999;29:950-6. (Pubitemid 29317806)
22. Simpson JL, Powell H, Boyle MJ, et al. Clarithromycin targets neutrophilic airway inflammation in refractory asthma. Am J Respir Crit Care Med 2008;177:148-55.
23. Sutherland ER, King TS, Icitovic N, et al. A trial of clarithromycin for the treatment of suboptimally controlled asthma. J Allergy Clin Immunol 2010;126:747-53.
24. Richeldi L, Ferrara G, Fabbri LM, et al. Macrolides for chronic asthma. Cochrane Database Syst Rev 2005; (4): CD002997.
25. Amayasu H, Yoshida S, Ebana S, et al. Clarithromycin suppresses bronchial hyperresponsiveness associated with eosinophilic inflammation in patients with asthma. Ann Allergy Asthma Immunol 2000;84:594-8. (Pubitemid 30418859)
26. Simpson JL, Powell H, Boyle MJ, et al. Clarithromycin targets neutrophilic airway inflammation in refractory asthma. Am J Respir Crit Care Med 2008;177:148-55.
27. Hübner C, Dietz A, Stremmel W, et al. Macrolide-induced Churg-Strauss syndrome in a patient with atopy. Lancet 1997;350:563. (Pubitemid 27348437)
28. Martin RJ, Kraft M, Chu HW, et al. A link between chronic asthma and chronic infection. J Allergy Clin Immunol 2001;107:595-601. (Pubitemid 32397743)
29. Ray WA, Murray KT, Hall K, et al. Azithromycin and the risk of cardiovascular death. N Engl J Med 2012;366:1881-90.
30. Malhotra-Kumar S, Lammens C, Coenen S, et al. Effect of azithromycin and clarithromycin therapy on pharyngeal carriage of macrolide-resistant streptococci in healthy volunteers: a randomised, double-blind, placebo-controlled study. Lancet 2007;369:482-90. (Pubitemid 46209315)
31. Haldar P, Brightling CE, Hargadon B, et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med 2009;360:973-84.
32. Pavord ID, Korn S, Howarth P, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet 2012;380:651-9.
33. Dweik RA, Boggs PB, Erzurum SC, et al. An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications. Am J Respir Crit Care Med 2011;184:602-15.